Related Videos
ASCENT-03 Study Presented by Sara Tolaney, MD, MPH
Dr. Sara Tolaney details research in The New England Journal of Medicine showing the ADC sacituzumab govitecan improved outcomes for patients with advanced triple-negative #BreastCancer ineligible for immune checkpoint inhibitors.
ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD
Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer.
Welcome Session | 2022-2023 EMBRACE MBC Virtual Forum Series
Nancy Lin, MD; Sara Tolaney, MD, MPH; and patient advocate Lianne Kraemer discuss new developments and promising areas of research in metastatic breast cancer at Dana-Farber and beyond.
